Botulinum toxin for LES spastic disorders

Linda Nguyen, Pankaj Jay Pasricha

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Botulinum toxin is one of the most potent neurotoxins available, blocking vesicular mediated neurotransmitter release from nerve endings and causing a paralysis or reduction in tone of the targeted muscle. Endoscopic injection of botulinum toxin has now been used for achalasia for nearly two decades, with grade I evidence for its efficacy. The experience with other spastic disorders of the esophagus is considerably more limited. Its main advantage is its simplicity and relative safety. On the other hand, its drawbacks include the limited duration of its effects and hence the requirement for repeat injections. Further, it is not very effective in younger patients. While not considered first-line therapy in most patients, it has nevertheless emerged as an alternative therapy for this condition in patients who are considered at high risk for more invasive methods of treatment such as pneumatic dilation or surgery. It is also of some value as a therapeutic trial in patients with equivocal clinical or manometric measures to assess the contribution of lower esophageal tone to symptoms.

Original languageEnglish (US)
Title of host publicationPrinciples of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders
PublisherSpringer New York
Pages889-896
Number of pages8
ISBN (Print)9781461437949, 9781461437932
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Muscle Spasticity
Botulinum Toxins
Injections
Esophageal Achalasia
Nerve Endings
Neurotoxins
Complementary Therapies
Paralysis
Esophagus
Neurotransmitter Agents
Dilatation
Therapeutics
Safety
Muscles

Keywords

  • Botulinum toxin
  • Endoscopic injection
  • LES spastic disorders
  • Muscle paralysis
  • Neurotoxin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nguyen, L., & Pasricha, P. J. (2013). Botulinum toxin for LES spastic disorders. In Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders (pp. 889-896). Springer New York. https://doi.org/10.1007/978-1-4614-3794-9_62

Botulinum toxin for LES spastic disorders. / Nguyen, Linda; Pasricha, Pankaj Jay.

Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders. Springer New York, 2013. p. 889-896.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nguyen, L & Pasricha, PJ 2013, Botulinum toxin for LES spastic disorders. in Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders. Springer New York, pp. 889-896. https://doi.org/10.1007/978-1-4614-3794-9_62
Nguyen L, Pasricha PJ. Botulinum toxin for LES spastic disorders. In Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders. Springer New York. 2013. p. 889-896 https://doi.org/10.1007/978-1-4614-3794-9_62
Nguyen, Linda ; Pasricha, Pankaj Jay. / Botulinum toxin for LES spastic disorders. Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders. Springer New York, 2013. pp. 889-896
@inbook{e1c57e255eb94c65b4a3d1d8597dee85,
title = "Botulinum toxin for LES spastic disorders",
abstract = "Botulinum toxin is one of the most potent neurotoxins available, blocking vesicular mediated neurotransmitter release from nerve endings and causing a paralysis or reduction in tone of the targeted muscle. Endoscopic injection of botulinum toxin has now been used for achalasia for nearly two decades, with grade I evidence for its efficacy. The experience with other spastic disorders of the esophagus is considerably more limited. Its main advantage is its simplicity and relative safety. On the other hand, its drawbacks include the limited duration of its effects and hence the requirement for repeat injections. Further, it is not very effective in younger patients. While not considered first-line therapy in most patients, it has nevertheless emerged as an alternative therapy for this condition in patients who are considered at high risk for more invasive methods of treatment such as pneumatic dilation or surgery. It is also of some value as a therapeutic trial in patients with equivocal clinical or manometric measures to assess the contribution of lower esophageal tone to symptoms.",
keywords = "Botulinum toxin, Endoscopic injection, LES spastic disorders, Muscle paralysis, Neurotoxin",
author = "Linda Nguyen and Pasricha, {Pankaj Jay}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-3794-9_62",
language = "English (US)",
isbn = "9781461437949",
pages = "889--896",
booktitle = "Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders",
publisher = "Springer New York",

}

TY - CHAP

T1 - Botulinum toxin for LES spastic disorders

AU - Nguyen, Linda

AU - Pasricha, Pankaj Jay

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Botulinum toxin is one of the most potent neurotoxins available, blocking vesicular mediated neurotransmitter release from nerve endings and causing a paralysis or reduction in tone of the targeted muscle. Endoscopic injection of botulinum toxin has now been used for achalasia for nearly two decades, with grade I evidence for its efficacy. The experience with other spastic disorders of the esophagus is considerably more limited. Its main advantage is its simplicity and relative safety. On the other hand, its drawbacks include the limited duration of its effects and hence the requirement for repeat injections. Further, it is not very effective in younger patients. While not considered first-line therapy in most patients, it has nevertheless emerged as an alternative therapy for this condition in patients who are considered at high risk for more invasive methods of treatment such as pneumatic dilation or surgery. It is also of some value as a therapeutic trial in patients with equivocal clinical or manometric measures to assess the contribution of lower esophageal tone to symptoms.

AB - Botulinum toxin is one of the most potent neurotoxins available, blocking vesicular mediated neurotransmitter release from nerve endings and causing a paralysis or reduction in tone of the targeted muscle. Endoscopic injection of botulinum toxin has now been used for achalasia for nearly two decades, with grade I evidence for its efficacy. The experience with other spastic disorders of the esophagus is considerably more limited. Its main advantage is its simplicity and relative safety. On the other hand, its drawbacks include the limited duration of its effects and hence the requirement for repeat injections. Further, it is not very effective in younger patients. While not considered first-line therapy in most patients, it has nevertheless emerged as an alternative therapy for this condition in patients who are considered at high risk for more invasive methods of treatment such as pneumatic dilation or surgery. It is also of some value as a therapeutic trial in patients with equivocal clinical or manometric measures to assess the contribution of lower esophageal tone to symptoms.

KW - Botulinum toxin

KW - Endoscopic injection

KW - LES spastic disorders

KW - Muscle paralysis

KW - Neurotoxin

UR - http://www.scopus.com/inward/record.url?scp=84955745006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955745006&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-3794-9_62

DO - 10.1007/978-1-4614-3794-9_62

M3 - Chapter

AN - SCOPUS:84955745006

SN - 9781461437949

SN - 9781461437932

SP - 889

EP - 896

BT - Principles of Deglutition: A Multidisciplinary Text for Swallowing and its Disorders

PB - Springer New York

ER -